Geographic Atrophy Ga clinical trials

Explore recruiting geographic atrophy ga clinical trials.

Recruiting geographic atrophy ga studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Geographic Atrophy Ga trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

Czechia, Hungary, Germany, Austria, Italy, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration

France, Austria, Spain, Poland, Italy, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Romania

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Czechia, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Belgium, Hungary, Poland, Italy, Denmark, Sweden +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Germany, Portugal, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Geographic Atrophy Ga trials by city

Geographic Atrophy Ga in Toronto Geographic Atrophy Ga in Vancouver Geographic Atrophy Ga in Montreal Geographic Atrophy Ga in Calgary Geographic Atrophy Ga in Edmonton Geographic Atrophy Ga in Ottawa Geographic Atrophy Ga in Winnipeg Geographic Atrophy Ga in Quebec City Geographic Atrophy Ga in Hamilton Geographic Atrophy Ga in Kitchener Geographic Atrophy Ga in London Geographic Atrophy Ga in Halifax Geographic Atrophy Ga in New York Geographic Atrophy Ga in Los Angeles Geographic Atrophy Ga in Chicago Geographic Atrophy Ga in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease